Overcoming the “Cell Count” Hurdle in Cord Blood Transplants
For years, umbilical cord blood has been a beacon of hope for patients with blood cancers and other hematologic diseases. Unlike bone marrow, cord blood stem cells do not require a stringent match to be effective, making them a vital resource for patients who lack a close donor—particularly those from multiethnic backgrounds.
However, a persistent challenge has hindered its widespread leverage: the “cell count” problem. A single unit of donated cord blood often contains too few stem cells to successfully treat an adult patient, leaving clinicians searching for ways to bridge the gap between available resources and patient needs.
Recent breakthroughs are now shifting this paradigm. By moving toward a “two-unit” approach, researchers are finding ways to ensure patients receive enough cellular support to achieve remission without compromising safety.
The Rise of Pooled Stem Cell Products: A New Blueprint for Recovery
The future of stem cell transplantation may lie in “pooled” products—the practice of combining cells from multiple donors to create a potent, expanded therapeutic tool. A landmark phase 2 clinical trial highlighted the efficacy of this approach, utilizing a product known as dilanubicel.
Developed by Dr. Colleen Delaney, a former Fred Hutch physician-scientist and current expert at Seattle Children’s Hospital, dilanubicel combines blood stem cells isolated from six to eight different cord blood units. These cells are then nurtured and expanded in a laboratory setting before being infused into the patient.
How the “Hybrid” Approach Works
Rather than relying on a single source, this new method uses a combination of a matched cord blood unit and the pooled dilanubicel product. The results published in the Journal of Clinical Oncology demonstrate a sophisticated division of labor within the body:
- Early Support: The pooled stem cells provide essential early immune support. In clinical observations, patients’ blood showed recovery driven by the pooled product just one week after transplant.
- Long-Term Stability: While the pooled cells do not engraft long-term, they create the necessary environment for the matched cord blood donor cells to establish a new, healthy immune system.
According to Dr. Filippo Milano, the study’s principal investigator and director of the Cord Blood Program at Fred Hutch, this marks the first time transplant patients have received cells from what essentially amounts to nine different human beings.
Breaking Barriers for Multiethnic Patients
One of the most significant trends in hematology is the push for health equity. Patients of multiethnic descent often face higher hurdles in finding a perfectly matched bone marrow donor, which can lead to dangerous delays in treatment.
The shift toward pooled cord blood products could democratize access to stem cell transplants. Because these products reduce the reliance on a singular, perfect match for the initial immune recovery, more patients can enter treatment sooner.
This evolution in care is especially critical for those with high-risk diseases who cannot afford to wait for a traditional donor search. By leveraging lab-expanded pooled cells, the medical community is moving toward a future where a patient’s ethnic background is no longer a barrier to receiving a life-saving transplant.
Reducing the Risks of Graft-Versus-Host Disease (GVHD)
The primary fear associated with stem cell transplantation has always been Graft-Versus-Host Disease (GVHD), a complication where the donor cells attack the recipient’s body. The goal of any new therapy is to maintain the “graft-versus-leukemia” effect while eliminating the “graft-versus-host” damage.
Data from recent trials suggests that the pooled approach may be significantly safer. In a study of 28 patients with leukemias and myelodysplastic syndrome, none of the patients experienced severe acute or chronic GVHD. 27 of those 28 patients (96%) survived at least one year.
This suggests that the combination of expanded pooled cells and a matched unit can provide the necessary immune “kickstart” without triggering the aggressive immune responses typically seen in high-dose adult transplants.
Clinical Outcomes at a Glance
The success of this approach is evident in the survival and remission rates:
- Survival Rate: 96% of trial participants survived at least one year post-transplant.
- Remission: All but one patient were alive and in remission at the end of the follow-up period.
- Resilience: Even in cases of relapse (such as one patient who relapsed 324 days post-transplant), subsequent treatments have led to continued remission.
For more information on the latest in oncology research, you can explore Fred Hutchinson Cancer Center’s latest releases or check our internal guide on Understanding Stem Cell Matching.
Frequently Asked Questions
Dilanubicel is a stem cell product created by combining and expanding blood stem cells from six to eight different umbilical cord blood units in a laboratory.
A standard transplant relies on a single donor unit. A pooled approach uses a “two-unit” strategy: one matched unit for long-term engraftment and a pooled product for immediate, early immune support.
In recent phase 2 trials, the treatment showed a 96% survival rate at one year, with no patients experiencing severe acute or chronic graft-versus-host disease (GVHD).
Patients with blood cancers or blood diseases who lack a close bone marrow donor match, particularly those from multiethnic backgrounds, benefit most from this approach.
Join the Conversation
Do you think pooled stem cell therapy will become the new standard of care for leukemia patients? We want to hear your thoughts in the comments below!
Subscribe to our newsletter for the latest breakthroughs in regenerative medicine and oncology.
